XML 54 R44.htm IDEA: XBRL DOCUMENT
v3.20.2

Segmentation of key figures (Details 6) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 11,347 | $ 11,764 | $ 23,630 | $ 22,870
Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (4.00%) |  | 3.00% |
Net sales, change in %, cc | (1.00%) |  | 6.00% |
Innovative Medicines |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 9,188 | 9,326 | $ 18,943 | 18,106
Innovative Medicines | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (1.00%) |  | 5.00% |
Net sales, change in %, cc | 1.00% |  | 7.00% |
Innovative Medicines | Oncology [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 3,548 | 3,606 | $ 7,196 | 6,927
Innovative Medicines | Oncology [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (2.00%) |  | 4.00% |
Net sales, change in %, cc | 1.00% |  | 6.00% |
Innovative Medicines | Oncology [member] | Tasigna [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 480 | 468 | $ 967 | 902
Innovative Medicines | Oncology [member] | Tasigna [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 3.00% |  | 7.00% |
Net sales, change in %, cc | 5.00% |  | 9.00% |
Innovative Medicines | Oncology [member] | Sandostatin [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 341 | 403 | $ 715 | 795
Innovative Medicines | Oncology [member] | Sandostatin [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (15.00%) |  | (10.00%) |
Net sales, change in %, cc | (13.00%) |  | (8.00%) |
Innovative Medicines | Oncology [member] | Afinitor/Votubia [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 266 | 401 | $ 562 | 774
Innovative Medicines | Oncology [member] | Afinitor/Votubia [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (34.00%) |  | (27.00%) |
Net sales, change in %, cc | (33.00%) |  | (26.00%) |
Innovative Medicines | Oncology [member] | Promacta/Revolade [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 422 | 349 | $ 825 | 656
Innovative Medicines | Oncology [member] | Promacta/Revolade [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 21.00% |  | 26.00% |
Net sales, change in %, cc | 23.00% |  | 28.00% |
Innovative Medicines | Oncology [member] | Tafinlar + Mekinist [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 371 | 340 | $ 737 | 637
Innovative Medicines | Oncology [member] | Tafinlar + Mekinist [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 9.00% |  | 16.00% |
Net sales, change in %, cc | 12.00% |  | 19.00% |
Innovative Medicines | Oncology [member] | Gleevec/Glivec [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 288 | 323 | $ 617 | 630
Innovative Medicines | Oncology [member] | Gleevec/Glivec [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (11.00%) |  | (2.00%) |
Net sales, change in %, cc | (8.00%) |  | 0.00% |
Innovative Medicines | Oncology [member] | Jakavi [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 310 | 284 | $ 628 | 542
Innovative Medicines | Oncology [member] | Jakavi [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 9.00% |  | 16.00% |
Net sales, change in %, cc | 14.00% |  | 20.00% |
Innovative Medicines | Oncology [member] | Exjade/Jadenu [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 163 | 253 | $ 335 | 491
Innovative Medicines | Oncology [member] | Exjade/Jadenu [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (36.00%) |  | (32.00%) |
Net sales, change in %, cc | (35.00%) |  | (31.00%) |
Innovative Medicines | Oncology [member] | Votrient [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 162 | 193 | $ 328 | 380
Innovative Medicines | Oncology [member] | Votrient [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (16.00%) |  | (14.00%) |
Net sales, change in %, cc | (14.00%) |  | (12.00%) |
Innovative Medicines | Oncology [member] | Kisqali [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 159 | 111 | $ 320 | 202
Innovative Medicines | Oncology [member] | Kisqali [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 43.00% |  | 58.00% |
Net sales, change in %, cc | 49.00% |  | 64.00% |
Innovative Medicines | Oncology [member] | Lutathera [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 105 | 109 | $ 217 | 215
Innovative Medicines | Oncology [member] | Lutathera [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (4.00%) |  | 1.00% |
Net sales, change in %, cc | (3.00%) |  | 1.00% |
Innovative Medicines | Oncology [member] | Kymriah [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 118 | 58 | $ 211 | 103
Innovative Medicines | Oncology [member] | Kymriah [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 103.00% |  | 105.00% |
Net sales, change in %, cc | 103.00% |  | 106.00% |
Innovative Medicines | Oncology [member] | Piqray [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 79 | 6 | $ 153 | 6
Innovative Medicines | Oncology [member] | Adakveo [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | 21 |  | 36 |
Innovative Medicines | Oncology [member] | Other [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 263 | 308 | $ 545 | 594
Innovative Medicines | Oncology [member] | Other [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (15.00%) |  | (8.00%) |
Net sales, change in %, cc | (13.00%) |  | (6.00%) |
Innovative Medicines | Pharmaceutical [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 5,640 | 5,720 | $ 11,747 | 11,179
Innovative Medicines | Pharmaceutical [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (1.00%) |  | 5.00% |
Net sales, change in %, cc | 1.00% |  | 8.00% |
Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 937 | 1,174 | $ 2,133 | 2,335
Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (20.00%) |  | (9.00%) |
Net sales, change in %, cc | (18.00%) |  | (7.00%) |
Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Lucentis [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 401 | 536 | $ 888 | 1,069
Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Lucentis [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (25.00%) |  | (17.00%) |
Net sales, change in %, cc | (24.00%) |  | (15.00%) |
Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Xiidra [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 79 |  | $ 169 |
Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Beovu [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | 34 |  | 102 |
Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Other [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 423 | 638 | $ 974 | 1,266
Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Other [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (34.00%) |  | (23.00%) |
Net sales, change in %, cc | (32.00%) |  | (21.00%) |
Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 1,025 | 886 | $ 2,045 | 1,683
Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 16.00% |  | 22.00% |
Net sales, change in %, cc | 17.00% |  | 23.00% |
Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Gilenya [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 738 | 825 | $ 1,510 | 1,591
Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Gilenya [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (11.00%) |  | (5.00%) |
Net sales, change in %, cc | (9.00%) |  | (4.00%) |
Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Zolgensma [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 205 | 15 | $ 375 | 15
Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Aimovig [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 33 | 24 | $ 69 | 42
Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Aimovig [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 38.00% |  | 64.00% |
Net sales, change in %, cc | 45.00% |  | 72.00% |
Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Mayzent [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 34 | 5 | $ 64 | 5
Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Other [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 15 | 17 | $ 27 | 30
Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Other [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (12.00%) |  | (10.00%) |
Net sales, change in %, cc | (26.00%) |  | (15.00%) |
Innovative Medicines | Pharmaceutical [member] | Respiratory [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 444 | 461 | $ 915 | 906
Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (4.00%) |  | 1.00% |
Net sales, change in %, cc | 0.00% |  | 5.00% |
Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Ultibro Group [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 149 | 166 | $ 309 | 323
Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Ultibro Group [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (10.00%) |  | (4.00%) |
Net sales, change in %, cc | (7.00%) |  | (1.00%) |
Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Xolair [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 289 | 290 | $ 596 | 571
Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Xolair [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 0.00% |  | 4.00% |
Net sales, change in %, cc | 4.00% |  | 8.00% |
Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Other [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 6 | 5 | $ 10 | 12
Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Other [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 20.00% |  | (17.00%) |
Net sales, change in %, cc | (10.00%) |  | (18.00%) |
Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 580 | 427 | $ 1,150 | 790
Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 36.00% |  | 46.00% |
Net sales, change in %, cc | 38.00% |  | 48.00% |
Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 580 | 421 | $ 1,149 | 778
Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 38.00% |  | 48.00% |
Net sales, change in %, cc | 40.00% |  | 50.00% |
Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Other [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations |  | 6 | $ 1 | 12
Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Other [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % |  |  | (92.00%) |
Net sales, change in %, cc |  |  | (98.00%) |
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 1,510 | 1,749 | $ 3,217 | 3,500
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (14.00%) |  | (8.00%) |
Net sales, change in %, cc | (9.00%) |  | (5.00%) |
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Galvus Group [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 279 | 320 | $ 617 | 635
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Galvus Group [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (13.00%) |  | (3.00%) |
Net sales, change in %, cc | (8.00%) |  | 1.00% |
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Diovan Group [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 268 | 283 | $ 542 | 544
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Diovan Group [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (5.00%) |  | 0.00% |
Net sales, change in %, cc | 0.00% |  | 4.00% |
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Exforge Group [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 238 | 264 | $ 496 | 531
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Exforge Group [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (10.00%) |  | (7.00%) |
Net sales, change in %, cc | (5.00%) |  | (3.00%) |
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Zortress/Certican [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 106 | 124 | $ 233 | 240
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Zortress/Certican [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (15.00%) |  | (3.00%) |
Net sales, change in %, cc | (12.00%) |  | 0.00% |
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Voltaren/Cataflam [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 82 | 95 | $ 174 | 208
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Voltaren/Cataflam [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (14.00%) |  | (16.00%) |
Net sales, change in %, cc | (11.00%) |  | (15.00%) |
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Neoral/Sandimmun(e) [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 96 | 110 | $ 197 | 213
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Neoral/Sandimmun(e) [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (13.00%) |  | (8.00%) |
Net sales, change in %, cc | (11.00%) |  | (5.00%) |
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Other [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 441 | 553 | $ 958 | 1,129
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Other [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | (20.00%) |  | (15.00%) |
Net sales, change in %, cc | (16.00%) |  | (12.00%) |
Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 1,144 | 1,023 | $ 2,287 | 1,965
Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 12.00% |  | 16.00% |
Net sales, change in %, cc | 13.00% |  | 18.00% |
Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Cosentyx [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 944 | 858 | $ 1,874 | 1,649
Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Cosentyx [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 10.00% |  | 14.00% |
Net sales, change in %, cc | 12.00% |  | 15.00% |
Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Ilaris [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales to third parties from continuing operations | $ 200 | $ 165 | $ 413 | $ 316
Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Ilaris [member] | Change over period [member] |  |  |  |
Disclosure of operating segments [line items] |  |  |  |
Net sales, change in % | 21.00% |  | 31.00% |
Net sales, change in %, cc | 23.00% |  | 33.00% |

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueFromSaleOfGoodsThirdParties
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
Namespace Prefix: | nvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc
Namespace Prefix: | nvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | nvs_ChangeOverPeriodAxis=nvs_PoPChangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_BusinessUnitAxis=nvs_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_LutatheraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_KymriahMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_PiqrayMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_AdakveoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_OtherProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_BusinessUnitAxis=nvs_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_OphthalmologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_XiidraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_BeovuMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_AimovigMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_MayzentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_RespiratoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_UltibroGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_XolairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_CardioMetabolicMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_EstablishedMedicinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ZortressCerticanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_VoltarenCataflamMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_NeoralSandimmunEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_ImmunologyHepatologyAndDermatologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |